![James Smith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Henry J. Smith | M | 85 |
NanoSmart Pharmaceuticals, Inc.
![]() NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | 18 años |
Paul F. Glidden | M | - |
NanoSmart Pharmaceuticals, Inc.
![]() NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | 12 años |
Daniel Thiel | M | - |
NanoSmart Pharmaceuticals, Inc.
![]() NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | - |
Kay Metis | F | - |
NanoSmart Pharmaceuticals, Inc.
![]() NanoSmart Pharmaceuticals, Inc. BiotechnologyHealth Technology NanoSmart Pharmaceuticals, Inc. is a privately-held corporation based in Laguna Hills, CA. The private company is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. Henry J. Smith has been the CEO of the company since 2006. | 9 años |
Gráfico relacional
Relaciones con varias empresas
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 4 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- James Smith
- Red Personal